Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies-Reference-Cited by-同舟云学术

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies

Published:2018-01 Issue:1 Volume:13 Page:85-96
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Dong Zhong-Yi,Zhang Chao,Li Yu-Fa,Su Jian,Xie Zhi,Liu Si-Yang,Yan Li-Xu,Chen Zhi-Hong,Yang Xue-Ning,Lin Jun-Tao,Tu Hai-Yan,Yang Jin-Ji,Zhou Qing,Sun Yue-Li,Zhong Wen-Zhao,Wu Yi-Long

Funder

Guangzhou Science and Technology Bureau

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference40 articles.

1. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer;Burdett;Cochrane Database Syst Rev,2015

2. Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives;Pakkala;Curr Opin Oncol,2016

3. Adjuvant immunotherapy for non-small cell lung cancer;Tucker;Cancer Treat Rev,2012

4. Adjuvant immunotherapy for solid tumors: from promise to clinical application;Mocellin;Cancer Immunol Immunother,2002

5. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results;Vansteenkiste;J Clin Oncol,2013

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High expression of eukaryotic elongation factor 1‐alpha‐2 in lung adenocarcinoma is associated with poor prognosis;Pathology International;2024-06-14

2. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation;Archives of Pathology & Laboratory Medicine;2024-04-16

3. Lung adenocarcinoma: selection of surgical approaches in solid adenocarcinoma from the viewpoint of clinicopathologic features and tumor microenvironmental heterogeneity;Frontiers in Oncology;2024-03-05

4. Molecular epidemiology study of programmed death ligand 1 and ligand 2 protein expression assessed by immunohistochemistry in extensive-stage small-cell lung cancer;Frontiers in Oncology;2024-01-09

5. Construction of a 12-Gene Prognostic Risk Model and Tumor Immune Microenvironment Analysis Based on the Clear Cell Renal Cell Carcinoma Model;Cancer Control;2024-01